InterHealth Zychrome Beats Chromium in Insulin Management Study

Zychrome was deemed 1.4-fold and 2.0-fold more effective than chromium picolinate in controlling insulin levels and insulin functions respectively, according to the company.

InterHealth Nutraceuticals Inc. (Benicia, CA) reports that its patent-pending Zychrome brand chromium proved significantly more effective than standard chromium picolinate in a three-month clinical trial. Zychrome was deemed 1.4-fold and 2.0-fold more effective than chromium picolinate in controlling insulin levels and insulin functions respectively, according to the company.

InterHealth’s research was presented at the 52nd American College of Nutrition Meeting held November 16–19.